FDA clears wireless cardiac monitor
IntriCon has received FDA 510(k) clearance for the first-generation wireless cardiac diagnostic monitoring device, which offers wireless transmission of patient data so physicians can continuously monitor cardiac events remotely.

The Centauri Ambulatory Patient ECG provides diagnostic evaluation of patients who experience transient symptoms that may suggest cardiac arrhythmia, according to a company release. The device offers continuous monitoring, arrhythmia detection and wireless transmission of recorded cardiac activity.

The Arden Hill, Minn.-based device developer expects to release the product in the third quarter.